Printer Friendly

Lescarden Increases Production Capacity for Catrix Wound Dressing.

[I TO: *hlthdata@aol.com ]]]]]]]

Business Editors

NEW YORK--(BUSINESS WIRE)--March 26, 2001

Lescarden Inc. announced today that it had recently completed the requisite inspection and qualification of an additional manufacturer of its Catrix(R) material.

This manufacturer is now qualified to supply Catrix(R) for the United States and European markets. The federal Spanish Ministry of Health acknowledged this qualification, after its on site inspection last Fall, and issued the required certificate of approval. This additional source of supply will enable the company to meet the growing demand for Catrix(R) Wound Dressing domestically, and to its Spanish licensee, ICN Iberica, S.A. ("ICNI").

Catrix(R) Wound Dressing is a topically applied cartilage-based powder, approved by the FDA and the Spanish Ministry of Health, for the treatment and management of chronic skin wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, second degree burns, and post radiation dermatitis. It is estimated that this segment of the wound care market is approximately $10 billion worldwide.

ICNI has been marketing Catrix(R) Wound Dressing in Spain for more than one year, and is presently awaiting for the Spanish Ministry of Health to establish a reimbursement rate for all patients, in Spain, who are prescribed this wound healing agent. A favorable rate could have significant impact upon sales in Spain. ICNI is a subsidiary of ICN Pharmaceuticals (NYSE: ICN), a multinational company that develops, manufactures and distributes pharmaceutical, research and diagnostic products in over 90 countries.

A company sponsored clinical trial of its Catrix(R) 10 Ointment was also recently concluded with highly favorable results. Patients having undergone Erbium laser peel procedures, (resurfaced facial skin), were administered Catrix 10 Ointment on half of the treated area, while the other half was administered the usual agent in such cases. The physicians who conducted this trial reported that the healing process was significantly better, and shorter, with the Catrix 10 Ointment. The complete clinical results are expected to be published shortly in a highly respected, peer reviewed, medical journal.

The company also reports that its representatives attended both the annual American Society For Dermatologic Surgery meeting in Denver, and the annual American Academy of Dermatology in Washington, where the company maintained a booth to display its topical products.

Lescarden Inc. (OTCBB:LCAR) is a biotechnology company engaged in the development of natural biologic materials for the treatment of chronic wounds, osteoarthritis and for dermatological uses. For more information, readers are directed to the company's web site at www.catrix.com or, inquiries may be made at 212-687-1050.
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Mar 26, 2001
Words:424
Previous Article:Insmed Incorporated Announces Access Information for Presentation At Banc of America Healthcare 2001 Conference.
Next Article:Siboney Corporation Releases Audited Results for 2000: Revenues - Up 63%, Net Income - Up 142%.


Related Articles
Solving the mysteries of wound care reimbursement.
Recent Developments in Wound Care Products.
Wound Care: What's Really Cost-Effective?
Experience with the malleable ear dressing, a versatile silicone-lined bandage for the auricle.
The effects of autologous platelet gel on wound healing.
Abdominal dressing system.
Unexpected economics of ulcer care protocols.
VALEANT MARKETS LESCARDEN'S CATRIX7 WOUND DRESSING.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters